Venous thromboembolism is a major cause of morbidity and mortality. Thrombosis can be caused by acquired or inherited factors, but the genetic contribution to thrombosis is not well defined. Genome wide association studies have recently uncovered new pathways that cause thrombotic disease in humans. The Lowenstein Lab uses human genetics to discover and characterize novel genes that regulate thrombosis and hemostasis. We collaborate with genetic epidemiologists who perform GWAS to identify genetic variants linked to vascular inflammation or thrombosis. We then characterize genetic loci linked to vascular inflammation or thrombosis. These approaches have revealed new pathways in endothelial cells and platelets that contribute to thrombosis and may lead to novel therapies to prevent abnormal bleeding and thrombosis. Current Projects: Genetic causes of venous thromboembolism | Genetic causes of abnormal endothelial activation | Epigenetic regulation of coagulation factor production

Our group is interested in a broad array of clinical and translational investigations spanning the evaluation of basic pathophysiology in patients undergoing cardiac procedures, development and evaluation of new therapeutic strategies, and improving patient selection and outcomes following interventional procedures. We are comprised of a core group of faculty and dedicated research nurses as well as fellows, residents, and students. Projects range from investigator-initiated single-center observational studies to industry-sponsored multicenter phase 3 randomized controlled trials. We have established a database of all patients who have undergone TAVR at Johns Hopkins, which is providing the basis for several retrospective analyses and will serve as the foundation for future studies of TAVR. We are also engaged in collaborative projects with other groups from the Department of Medicine and other Departments including Cardiac Surgery, Anesthesiology, Radiology, Psychiatry, and Biomedical Engineering. Members of our group are actively involved with the Johns Hopkins Center for Bioengineering Innovation and Design (CBID) in the development of novel minimally-invasive cardiovascular devices.

The Michael B. Streiff Lab conducts clinical and laboratory research of thrombophilia associated with malignancy. We are interested in the application of novel coagulation assays to explore the pathogenesis of thrombosis and the development of strategies to enhance the clinical management of anti-thrombotic agents.

The Rakhi Naik Lab studies sickle cell disease. We focus on complications related to the disease, including chronic kidney disease and venous thromboembolism. By defining the risks and factors for diseases related to the sickle cell trait, we hope to improve genetic counseling and screening and treatment recommendations. Other research in the lab examines the epidemiology and unique mechanisms of thrombosis in patients with hemoglobin disorders. Specifically, we are trying to identify mechanisms of hypercoagulability and develop treatments for patients with hemoglobinopathies.